Earnings Feed
Start Free
AbbVie Inc.·4

Feb 20, 6:35 PM ET

Purdue David Ryan 4

4 · AbbVie Inc. · Filed Feb 20, 2026

Research Summary

AI-generated summary of this filing

Updated

AbbVie SVP David Purdue Receives 10,946 Performance Shares

What Happened

  • David Ryan Purdue, Senior Vice President and Controller of AbbVie (ABBV), was credited with a total of 10,946 shares through awards and an account balance on Feb 18, 2026. The filing lists awards of 2,505; 890; 1,292; and 1,384 shares (all $0 per share, performance-vested awards) plus 4,875 shares reported as a derivative balance. These awards/prior holdings have a reported acquisition price of $0 and will be issued or reflected on Feb 28, 2026. The performance-vesting conditions for the awards were certified by AbbVie’s Compensation Committee and released on Feb 18, 2026.

Key Details

  • Transaction date(s): Feb 18, 2026; Form 4 filed Feb 20, 2026 (appears timely).
  • Shares granted/credited: 2,505 + 890 + 1,292 + 1,384 + 4,875 = 10,946 shares; acquisition price reported $0.
  • Issuance date: The performance-based shares from the awards are scheduled to be issued on Feb 28, 2026 (see footnotes).
  • Notable footnotes:
    • F1–F4: Four performance-vesting awards (granted in 2023–2025) whose performance conditions were certified and released; shares to be issued Feb 28, 2026.
    • F5: 4,875-share balance in the AbbVie Savings program as of Feb 20, 2026 (includes dividend reinvestment).
    • F6: Filing also references an employee stock option award under the company plan with staged exercisability (1,625 shares each year on Feb 18, 2027–2029).
  • Shares owned after transaction: The filing does not specify total post-transaction beneficial ownership in this summary line.

Context

  • These transactions are awards and an account balance being recorded/issued, not open-market purchases or sales. Performance-based awards reflect achievement of pre-set metrics (e.g., EPS, relative TSR, or return on equity per the footnotes) and do not necessarily indicate an insider’s immediate trading intent. The derivative designation on the 4,875 shares reflects reporting of a savings-plan balance rather than a new cash purchase.

Insider Transaction Report

Form 4
Period: 2026-02-18
AbbVie Inc.ABBV
Purdue David Ryan
SVP, Controller
Transactions
  • Award

    Common Stock, $0.01 par value

    [F1]
    2026-02-18+2,505→ 7,010 total
  • Award

    Common Stock, $0.01 par value

    [F2]
    2026-02-18+890→ 7,900 total
  • Award

    Common Stock, $0.01 par value

    [F3]
    2026-02-18+1,292→ 9,192 total
  • Award

    Common Stock, $0.01 par value

    [F4]
    2026-02-18+1,384→ 10,576 total
  • Award

    Option (Right to buy)

    [F6]
    2026-02-18+4,875→ 4,875 total
    Exercise: $230.04Exp: 2036-02-17→ Common Stock (4,875 underlying)
Holdings

  • Common Stock, $0.01 par value

    [F5]
    (indirect: By Trust)
    543
Footnotes (6)
  • [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
  • [F5]Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
  • [F6]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 1,625 on February 18, 2027, 1,625 on February 18, 2028, and 1,625 on February 18, 2029.
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for David R. Purdue|2026-02-20

Documents

1 file
  • 4
    form4-02202026_060215.xmlPrimary